Anti-Cystatin-9 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the N-terminus of mature human Cystatin-9 (CST9, Q5W186), validated for WB.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-
UniProt
Q5W186
Size
100ug
Cat. #
RP1Cystatin9

In stock

SKU
RP-Cystatin9

Options

As low as: $130.00

Target Overview

Cystatin-9 (CST9; UniProt Q5W186), also referred to as cystatin-like molecule, is a 159-amino acid secreted protein belonging to the type 2 cystatin superfamily of cysteine protease inhibitors. The mature protein follows the canonical cystatin fold and is processed from a precursor containing an N-terminal signal peptide consistent with constitutive secretion. Like other type 2 cystatins, CST9 is predicted to act on papain-family cysteine peptidases (cathepsins B, H, L, S), although a definitive endogenous substrate profile has not been established and direct enzymatic inhibition data for CST9 remain limited relative to better-characterized family members such as cystatin C. Expression has been documented in testis, with additional transcript detected in hematopoietic and immune compartments. Reported activities extend beyond classical protease inhibition: CST9 has been implicated in testicular development by similarity to murine orthologs, in hematopoietic differentiation and inflammatory signaling (PubMed 12535658), and in host defense, where recombinant CST9 displays immunomodulatory and direct antimicrobial activity against Francisella tularensis (PubMed 23922243). Researchers studying secreted cysteine protease inhibitors, reproductive biology, innate immunity against intracellular bacterial pathogens, and parasite-host interactions use CST9 antibodies to track protein expression, secretion, and tissue distribution. Triple Point Biologics offers two rabbit polyclonal antibodies against human Cystatin-9 (RP1Cystatin9, RP2Cystatin9), both raised against the amino-terminus of the mature protein and validated for Western blot on human samples.

Background

CST9 sits within a chromosome 20 cluster of cystatin genes (CST8–CST11) that are predominantly expressed in the male reproductive tract. The gene was originally cloned and characterized in the context of testis-specific cystatin biology, and orthologous studies suggest involvement in spermatogenesis and epididymal sperm maturation. Beyond the reproductive system, CST9 transcripts have been detected in bone marrow and peripheral blood cells, leading to proposals that the protein contributes to hematopoietic differentiation or to the regulation of inflammatory responses. A notable functional thread is innate immunity. Recombinant human CST9 has been shown to exert both direct antimicrobial activity and macrophage-modulating effects against Francisella tularensis, the causative agent of tularemia, positioning the protein as part of the cysteine protease inhibitor arm of host defense. More recently, work on Toxoplasma gondii has identified a parasite cyst wall protein designated CST9 that elicits acute humoral responses in humans and mice and confers protection against chronic infection upon immunization (Saldarriaga Cartagena et al., 2025, Microb Pathog). Investigators working with anti-CST9 reagents in infection models should confirm species and parasite-versus-host origin of the target, as nomenclature overlap can create ambiguity in the literature. CST9 has also surfaced in unbiased genetic and biomarker screens. GWAS in Middle Eastern populations identified CST9-region variants associated with preserved kidney function (Mohamed et al., 2022, BMC Med), and CST9 has been flagged in analyses examining shared genetic architecture between Alzheimer's disease and type 2 diabetes (Boukhalfa et al., 2023). cfDNA methylation profiling in endometrial polyps and proteomic biomarker studies in schizophrenia have likewise included CST9 among candidate loci or interactors. These reports remain associative, but they have broadened interest in CST9 beyond its initial reproductive-tract characterization. The TPB antibodies (RP1Cystatin9, RP2Cystatin9) are intended for endogenous detection of human CST9 in tissue lysates, fixed sections, and cultured cells.

References

  1. Saldarriaga Cartagena AM et al (2025) Toxoplasma cyst wall CST9 elicits an acute-associated humoral response in humans and mice and protects against chronic infection in immunized mice. Microb Pathog. PubMed · DOI
  2. Boukhalfa W et al (2023) Decoding the genetic relationship between Alzheimer's disease and type 2 diabetes: potential risk variants and future direction for North Africa. Front Aging Neurosci. PubMed · DOI
  3. Li XH et al (2022) cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps. Cells. PubMed · DOI
  4. Mohamed SA et al (2022) GWAS in people of Middle Eastern descent reveals a locus protective of kidney function—a cross-sectional study. BMC Med. PubMed · DOI
  5. Yang M et al (2019) Kininogen-1 as a protein biomarker for schizophrenia through mass spectrometry and genetic association analyses. PeerJ. PubMed · DOI

Additional Specifications

Gene Symbol CST9
UniProt ID Q5W186
Host Species Rabbit
Species Reactivity Validated- Human
Potential-
Pack Size 100ug
Immunogen (Aminoterminus of mature Cystatin-9.)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 29-79.
Immunogen (Carboxyterminus of mature Cystatin-9.)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 109-159.
Alternate Names Cystatin-9, CST9, Cystatin-like molecule, CLM, Testatin-related cystatin

Frequently Asked Questions

What molecular weight band should I expect for Cystatin-9 on Western blot?

Cystatin-9 runs at approximately 17-18 kDa under reducing conditions, corresponding to the mature secreted protein of 159 amino acids after signal peptide cleavage. The predicted molecular weight from sequence is ~17 kDa. Because CST9 is a secreted cystatin, you may observe slightly diffuse migration depending on sample type and any post-translational modifications. In cell lysates expressing low endogenous levels, concentration or enrichment of conditioned media may be necessary. Standard sample preparation with reducing agent and boiling is appropriate for this target.

Does this antibody cross-react with other cystatin family members?

Cross-reactivity with other type 2 cystatins has not been systematically characterized for this polyclonal reagent. The cystatin superfamily shares significant structural homology, particularly within the conserved cystatin fold. We recommend including samples known to express related cystatins (such as cystatin C, D, or SN) as specificity controls if your experimental system co-expresses multiple family members. Pre-absorption or siRNA knockdown controls are advisable when distinguishing CST9 signal from related proteins in complex tissues, particularly in testis or immune cell lysates where multiple cystatins are co-expressed.

What dilution should I start with for Western blot of Cystatin-9?

We validate this antibody at 1:1000 for Western blot. This serves as a reliable starting point for most applications with standard protein loads of 20-50 µg per lane. Because endogenous CST9 expression is relatively restricted and can be low in many cell types, you may need to optimize upward to 1:500 if signal is weak, or extend exposure time. For recombinant CST9 or overexpression systems, 1:2000 to 1:5000 may be sufficient. Titre the antibody against your specific sample type and detection system for optimal signal-to-noise.

Which tissues or cell lines are good positive controls for Cystatin-9 expression?

Testis tissue is the most reliable positive control for CST9, where expression is well-documented. Among cell lines, transcript data suggest hematopoietic and immune-related lines may express CST9, though protein-level validation is limited in the literature. If working with cell lines, consider screening several candidates by RT-PCR before committing to Western blot optimization. Recombinant CST9 protein is advisable as a reference standard to confirm antibody recognition and establish expected migration. Negative controls from tissues with undetectable CST9 transcript, such as liver or skeletal muscle, help assess specificity.

Is this Cystatin-9 antibody validated in species other than human?

This antibody is validated specifically for human Cystatin-9. Predicted cross-reactivity with other species depends on sequence homology in the epitope region, which has not been empirically tested. If you are working with mouse, rat, or other model organisms, alignment of the CST9 ortholog sequence against human is advisable before proceeding. We cannot guarantee performance in non-human samples without direct validation. For non-human studies, consider titrating the antibody across a dilution series and including both positive control lysates and blocking peptide controls to assess specificity empirically.

Can I use this antibody for immunohistochemistry or immunofluorescence?

Triple Point Biologics antibodies are routinely validated for IHC and immunofluorescence in addition to Western blot. While we have not published specific protocols for CST9 IHC, the reagent is suitable for testing in fixed tissue sections. Start with standard antigen retrieval protocols (citrate buffer, pH 6.0, or Tris-EDTA, pH 9.0) and an antibody dilution of 1:100 to 1:200. Because CST9 is a secreted protein, expect diffuse extracellular or perinuclear Golgi-associated staining in expressing cells. Validate staining patterns with known CST9-positive tissue such as testis and include isotype or pre-immune controls.

What is the expected subcellular localization of Cystatin-9?

Cystatin-9 is a secreted protein with an N-terminal signal peptide that directs it through the classical secretory pathway. In producing cells, you may observe CST9 signal in the endoplasmic reticulum and Golgi before secretion. Once secreted, CST9 localizes extracellularly, where it presumably functions as a cysteine protease inhibitor. In Western blots of cell lysates, you will detect intracellular precursor and mature forms; conditioned media from cultured cells will contain the secreted mature protein. For immunofluorescence, expect perinuclear and secretory vesicle staining in expressing cells, with extracellular accumulation depending on culture conditions.

How should I store this Cystatin-9 antibody and what is the shelf life?

Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can compromise titre and increase background. The antibody is supplied in a stabilized formulation and typically remains stable for at least 12 months from the date of receipt when stored properly. Once thawed, an aliquot can be held at 4°C for up to one month for convenient repeated use. Do not store diluted antibody; prepare working dilutions fresh in blocking buffer immediately before use. If you observe increased background or loss of signal over time, prepare a fresh aliquot from frozen stock.

Western blot validation for RP-Cystatin9 — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Cystatin-9: Aminoterminus of mature Cystatin-9 — WB validation
WB · Panel 1 Cystatin-9: Aminoterminus of mature Cystatin-9
Cystatin-9: Carboxyterminus of mature Cystatin-9 — WB validation
WB · Panel 2 Cystatin-9: Carboxyterminus of mature Cystatin-9

Custom validation studies available on request — contact us.

Also known as:

  • Cystatin-9
  • CST9
  • Cystatin-like molecule
  • CLM
  • Testatin-related cystatin
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →